A program to convert patients from trade-name to generic clozapine

Area of Science:

• Pharmacology
• Psychiatry

Background:

• Missouri Department of Mental Health mandated conversion from trade-name to generic clozapine in psychiatric facilities.
• A conversion program was developed to assess efficacy and tolerability of generic clozapine.

Purpose of the Study:

• To determine if therapeutic response and tolerability are equivalent between generic and trade-name clozapine.
• To assess the necessity of changes in white blood cell and absolute neutrophil count monitoring post-conversion.

Main Methods:

• A hospitalwide protocol was implemented to monitor patients during conversion to generic clozapine.
• Efficacy was assessed using the Brief Psychiatric Rating Scale (BPRS).
• Tolerability and monitoring parameters (white blood cell and absolute neutrophil counts) were evaluated.

Main Results:

• Most patients (24/24) successfully converted to generic clozapine.
• The majority of patients showed no significant changes (>5 points) in BPRS scores.
• A statistically significant difference was observed in BPRS score changes for 22 patients (p=0.0139).
• 14 patients (58%) experienced a decrease in BPRS scores, while 10 (42%) had an increase, with 50% of those increasing showing a 10% or less rise.

Conclusions:

• The conversion program successfully transitioned all patients to generic clozapine.
• Generic clozapine demonstrated comparable efficacy and tolerability to the trade-name formulation.
• No changes in monitoring protocols for white blood cell and absolute neutrophil counts were deemed necessary.